Cas:475469-15-9 3-Boc-amino-3-(hydroxymethyl)pyrrolidine manufacturer & supplier

Chemical Name:3-Boc-amino-3-(hydroxymethyl)pyrrolidine

CAS.NO:475469-15-9

Synonyms:tert-Butyl [3-(hydroxymethyl)pyrrolidin-3-yl]carbamate;tert-butyl N-[3-(hydroxymethyl)pyrrolidin-3-yl]carbamate;3-Boc-amino-3-(hydroxymethyl)pyrrolidine;Carbamic acid, N-[3-(hydroxymethyl)-3-pyrrolidinyl]-, 1,1-dimethylethyl ester;2-Methyl-2-propanyl [3-(hydroxymethyl)-3-pyrrolidinyl]carbamate

Molecular Formula:C₁₀H₂₀N₂O₃

Molecular Weight:216.277

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:346.9±35.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.504

PSA:70.59000

Exact Mass:216.147400

LogP:0.24

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like tert-Butyl [3-(hydroxymethyl)pyrrolidin-3-yl]carbamate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Methyl-2-propanyl [3-(hydroxymethyl)-3-pyrrolidinyl]carbamate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Boc-amino-3-(hydroxymethyl)pyrrolidine Use and application,3-Boc-amino-3-(hydroxymethyl)pyrrolidine technical grade,usp/ep/jp grade.

Related News: In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say. 3-Boc-amino-3-(hydroxymethyl)pyrrolidine manufacturer After testing, our quality assurance staff confirms that everything has been performed correctly in accordance with GMP from manufacturing of API to quality testing. 3-Boc-amino-3-(hydroxymethyl)pyrrolidine supplier f you’ve traveled in or transited through mainland China, you won’t be allowed into New Zealand unless you’re a New Zealand national. 3-Boc-amino-3-(hydroxymethyl)pyrrolidine vendor Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely. 3-Boc-amino-3-(hydroxymethyl)pyrrolidine factory In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say.